hormones in the pathgenesis and treatment of ks.

NLM AIDSLINE Hormones in the pathgenesis and treatment of KS. Gill PS; M.D. University of Southern California School of Medicine
November 30, 1996

3rd Conf Retro and Opportun Infect. 1996 Jan 28-Feb 1;:177. Unique Kaposi's sarcoma (KS) develops in a variety of clinical settings and is the most common tumor seen in patients with HIV infection. KS develops most commonly in men compared to women (15:1) regardless of the clinical setting. It thus appears that sex hormones play a role in the pathogenesis of this disease. However the lack of sex hormone receptors in KS tissues argue against the direct effect of these hormones. Metabolic products of sex hormones which do not bind the receptors may have direct effects and will be discussed. The development and progression of KS secondary to the exogenous use of glucocorticoids has been reported in HIV infected and uninfected individuals. Furthermore the direct stimulatory effects of glucocorticoids enchance KS cell growth through the regulation of various growth regulatory factors. Lastly I will discuss the results of clinical trials of human chorionic gonadotrophin in the treatment of KS. These studies are based on the findings fo Drs. Lunardi-Iskandar, Bryant and Gallo (Nature374:64-68, 1995) who showed that KS cell lines do not propagate in pregnant mice, that hCG inhibits KS cell growth in vitro and in the mouse model. In collaboration with Dr. Gallo's group we have studied the direct effect of hCG in humans. HCG was injected directly in the tumor lesions in a dose escalating schema. Furthermore at the highest dose level tested (2,000 IU), a double blind trial comparing hCG is active. The details of the results will be presented. Antineoplastic Agents, Hormonal/THERAPEUTIC USE Female Glucocorticoids/THERAPEUTIC USE HIV Infections/COMPLICATIONS Human Male Sarcoma, Kaposi's/ETIOLOGY/THERAPY Sex Hormones/THERAPEUTIC USE ABSTRACT

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Photographs from A Day with HIV Now Online Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 COLORADO: Boulder Groups Honor More Than 150 Local AIDS Victims PENNSYLVANIA: Area Residents Screened for Hepatitis C on Sunday COLORADO: Peer to Peer: Teens Work to Educate Peers on Pregnancy, STDs at CCHS OREGON: Portland Barefoot 3 x 3 Benefit Tournament to Draw Hundreds to Northeast Portland TEXAS: Temple - Wellness and Sexual Health Classes Helping Kids to Abstain CONNECTICUT: Yale Researchers Urge More Street Work When Studying People With Both HIV, Hepatitis C JAMAICA: AIDS Awareness Workshop Organised for High-School Students EUROPE: EU Issues Stringent Sharps Regulations CALIFORNIA: $50,000 Prisoner Prescription: Inmates Get Expensive Hepatitis C Treatment Tentative approval of lamivudine and tenofovir disoproxil fumarate Tablets, 300 mg/300 mg CALIFORNIA: $50,000 Prisoner Prescription: Inmates Get Expensive Hepatitis C Treatment ITALY: HIV Is No Barrier to Successful Liver Transplant for Cancer Treatment Viet Nam: South-South learning helps prepare for sustainable provision of AIDS treatment China and Africa Discuss Health Treatment Problems Simpler ARV treatment begins in Eastern Cape AFRICA: Less-Used HIV Treatment for African Children More Effective CANADA: Drug-Resistant Gonorrhea Prompts New Treatment Guidelines in Ont. Less-Used HIV Treatment for African Children More Effective The Next Step in Drug Treatment Boehringer Ingelheim's Faldaprevir-Based Treatment Regimen Achieved Viral Cure in up to 80 Percent of Patients with Hepatitis C in Phase 3 Pivotal Trial
Information in this article was accurate in November 30, 1996. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.